CRISPR Therapeutics AG (CRSP)

55,89 +0,82 (+1,49 %) À la clôture : 04:00PM EDT

CRISPR Therapeutics AG

Baarerstrasse 14
Zug 6300
Switzerland
41 41 561 32 77
https://www.crisprtx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 407

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Samarth Kulkarni Ph.D.	CEO & Chairman	1,35M	4,06M	1978
Dr. Raju Yashaswi Prasad Ph.D.	Chief Financial Officer	880,1k	S.O.	1984
Mr. James R. Kasinger	General Counsel & Secretary	734,72k	S.O.	1972
Mr. Shaun Foy	Founder	S.O.	S.O.	S.O.
Dr. Emmanuelle Marie Charpentier	Co-Founder & Scientific Advisory Board Member	S.O.	S.O.	S.O.
Dr. Craig C. Mello Ph.D.	Scientific Founder & Advisory Board Member	S.O.	S.O.	S.O.
Dr. Chad A. Cowan Ph.D.	Scientific Founder	S.O.	S.O.	S.O.
Dr. Matthew Porteus M.D., Ph.D.	Scientific Founder & Advisory Board Member	S.O.	S.O.	1966
Dr. Daniel G. Anderson Ph.D.	Scientific Founder & Advisory Board Member	S.O.	S.O.	S.O.
Mr. Stephen Kennedy	Head of Technical Operations	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Gouvernance d’entreprise

L’ISS Governance QualityScore de CRISPR Therapeutics AG en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 4; Société : 9; Droits des actionnaires : 2; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.